Typhim Vi SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN 25 ug/.5mL Injection, Solution, 1 syringe — NDC 49281-790-51 (Billing 49281-0790-51)
This is a package of 1 syringe of Typhim Vi SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN 25 ug/.5mL Injection, Solution from Sanofi Vaccines US Inc., marketed since Nov 1994 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 49281-790-51 alone.
- Record
- FDA NDC Directory package listing · Vaccine
- Code segments
- 49281 labeler · 790 product · 51 package
- Package marketed since
- Nov 28, 1994
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 4928179051 5
- FDA record last changed
- Oct 8, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 022678
- GCN: 48422
- HICL (First Databank): 009656
- AHFS class code: 80:12.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $308.33 | $154.17 / 0.5 ml |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 9, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 49281-0790-20 49281-790-20 Main listing | 1 VIAL, MULTI-DOSE in 1 PACKAGE / 10 mL in 1 VIAL, MULTI-DOSE | 1994-11-28 | — | Active |
| 49281-0790-51 You're viewing this | 1 SYRINGE in 1 PACKAGE / .5 mL in 1 SYRINGE | 1994-11-28 | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Typhim Vi SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN 25 ug/.5mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Typhim Vi 25 ug/.5mLthis 49281-0790-51 | Sanofi | 1 syringe | — | — | FDA listed | — |
| Typhim Vi 25 ug/.5mL 50090-1493-00 | A-S | 1 syringe | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Purple Book · refreshed Oct 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Oct 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
1.25 mg / 0.5 mL
UNII 339NCG44TV
Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
-
4.15 mg / 0.5 mL
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
0.065 mg / 0.5 mL
UNII 94255I6E2T
Sodium phosphate dibasic dihydrate is a salt that helps control the acidity level of a medicine. It acts as a buffer and pH regulator to keep the medication stable and effective.
-
0.023 mg / 0.5 mL
UNII 5QWK665956
A salt derived from phosphoric acid and sodium, used primarily as a buffer to control the acidity or pH of a medication, helping keep it stable during storage and use.
-
0.5 mL / 0.5 mL
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Sanofi Vaccines US Inc. labeler code 49281
- FLUZONE TIV SH 2026 INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACT 15 ug/.5mL; 15 ug/.5mL Injection, Suspension NDC 49281-626-50
- FLUZONE TRIVALENT NORTHERN HEMISPHERE INFLUENZA A VIRUS A/Victoria/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Croatia/10136/RV/2023 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED) 15 ug/.5mL; 15 ug/.5mL Injection, Suspension NDC 49281-643-15
- FLUZONE TRIVALENT NORTHERN HEMISPHERE INFLUENZA A VIRUS A/Switzerland/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Michigan/105/2025 SAN-049A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/Tokyo/EIS13-175/2025 ANTIGEN (FORMALDEHYDE INACT 15 ug/.5mL; 15 ug/.5mL Injection, Suspension NDC 49281-645-15
- FLUBLOK TRIVALENT NORTHERN HEMISPHERE INFLUENZA A VIRUS A/WEST VIRGINIA/30/2022 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/District of Columbia/27/2023 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 RECOMBINANT HEMAGGLUTININ ANTIGEN 45 ug/.5mL; 45 ug/.5mL Injection NDC 49281-725-10
- FLUBLOK TRIVALENT NORTHERN HEMISPHERE INFLUENZA A VIRUS A/Missouri/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/Darwin/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/Pennsylvania/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN 45 ug/.5mL; 45 ug/.5mL Injection NDC 49281-726-10
- TUBERSOL Tuberculin Purified Protein Derivative 5 [iU]/.1mL Injection, Solution NDC 49281-752-21
- IPOL POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED), POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED), and POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 1 ANTIGEN (FORMALDEHYDE INACTIVATED) 40 [D'ag'U]/.5mL; 2 ANTIGEN (FORMALDEHYDE INACTIVATED) 8 [D'ag'U]/.5mL; 3 ANTIGEN (FORMALDEHYDE INACTIVATED) 32 [D'ag'U]/.5mL Injection, Suspension NDC 49281-860-10
- Diluent Sodium Chloride 4.5 mg/.5mL Injection NDC 49281-912-05
- YF-VAX YELLOW FEVER VIRUS STRAIN 17D-204 LIVE ANTIGEN 17D-204 LIVE ANTIGEN 4.74 [PFU]/.5mL Injection, Powder, Lyophilized, For Suspension NDC 49281-915-01
- Fluzone Quadrivalent Northern Hemisphere INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Croatia/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 15 ug/.5mL; 15 ug/.5mL Injection, Suspension NDC 49281-926-50
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |